乳腺癌组织中GATA3和GLUT-1的表达及临床意义-东南大学学报医学版

乳腺癌组织中GATA3和GLUT-1的表达及临床意义

单位：1. 湖南中医药大学第一附属医院病理科, 湖南长沙 471012;
2. 湖南省康复医院放射科, 湖南长沙 471012;
3. 长沙珂信肿瘤医院肿瘤科, 湖南长沙 471012

分类号：R737.9

出版年·卷·期（页码）：2025·44·第三期（466-472）

摘要：

目的: 探究GATA结合蛋白3(GATA3)、葡萄糖转运蛋白-1(GLUT-1)在乳腺癌组织中的表达及临床意义。方法: 选取2019年5月至2021年5月手术治疗的118例乳腺癌患者,手术中留存癌组织标本和癌旁组织标本进行研究。同时收集整理其TNM分期、淋巴结转移等临床资料。采用免疫组织化学法检测GATA3、GLUT-1表达水平;分析乳腺癌患者GATA3、GLUT-1表达水平与临床病理特征的关系;相关性采用Spearman等级相关分析;用Kaplan-Meier法分析GATA3、GLUT-1表达与患者预后关系;多因素Cox回归分析乳腺癌患者预后的影响因素。结果: GATA3阳性表达率在乳腺癌组织为27.97%,低于癌旁组织(P＜0.05);GLUT-1阳性表达率在乳腺癌组织为73.73%,高于癌旁组织(P＜0.05)。TNM分期为Ⅲ期、肿瘤直径≥2 cm、发生淋巴结转移患者的乳腺癌组织GATA3阳性表达比例明显低于TNM分期为Ⅰ~Ⅱ期、未发生淋巴结转移、肿瘤直径＜2 cm的乳腺癌患者(P＜0.05);GLUT-1阳性表达比例明显高于TNM分期为Ⅰ~Ⅱ期、未发生淋巴结转移、肿瘤直径＜2 cm的乳腺癌患者(P＜0.05)。乳腺癌组织GATA3与GLUT-1表达呈负相关(r=-0.229,P＜0.05)。乳腺癌组织GATA3阳性患者3年生存率(25/33,75.76%)高于GATA3阴性表达患者(20/85,23.53%)(χ²=27.485,P＜0.05);GLUT-1阳性患者3年生存率(21/87,24.14%)低于GLUT-1阴性表达患者(24/31,77.42%)(χ²=27.503,P＜0.05)。GATA3、GLUT-1、TNM分期、肿瘤直径及淋巴结转移是乳腺癌预后的影响因素(P＜0.05)。结论: 乳腺癌组织GATA3、GLUT-1表达与患者TNM分期等临床病理特征及预后有密切联系。

Objective: To investigate the expressions and clinical significance of GATA binding protein 3(GATA3) and glucose transporter type-1(GLUT-1) in breast cancer. Methods: A total of 118 patients with breast cancer who were treated surgically in our hospital from May 2019 to May 2021 were collected, and cancer tissue specimens and paracancerous tissue specimens were retained during the surgery for research. Simultaneously, clinical data such as TNM staging and lymph node metastasis were collected and organized. Immunohistochemistry was applied to detect the expression levels of GATA3 and GLUT-1. The relationship between the expression levels of GATA3 and GLUT-1 and the clinicopathological characteristics in the breast cancer patients was analysed; the correlation was analysed by Spearman rank correlation analysis. The relationship between the expressions of GATA3 and GLUT-1 and the prognosis of patients was analysed by the Kaplan-Meier method. The multifactorial Cox regression analyses were used to analyse the influencing factors of the prognosis of breast cancer patients. Results: The positive expression rate of GATA3 was 27.97% in breast cancer tissues, which was lower than that of paracancerous tissues(P<0.05), and the positive expression rate of GLUT-1 was 73.73% in breast cancer tissues, which was higher than that of paracancerous tissues(P<0.05). The proportion of breast cancer tissues with GATA3 positive expression was significantly lower in patients with TNM stage Ⅲ, tumour diameter ≥2 cm and lymph node metastasis than that in breast cancer patients with TNM stage Ⅰ-Ⅱ, no lymph node metastasis and tumour diameter <2 cm(P<0.05), the proportion of GLUT-1 positive expression was significantly higher than that of breast cancer patients with TNM stage Ⅰ-Ⅱ, no lymph node metastasis and tumour diameter <2cm(P<0.05). GATA3 was negatively correlated with GLUT-1 expression in breast cancer tissues(r=-0.229, P<0.05).The 3-year survival rate of patients with GATA3-positive breast cancer tissues(25/33, 75.76%) was higher than that of patients with GATA3-negative expression(20/85, 23.53%)(χ²=27.485, P<0.05).The 3-year survival rate of GLUT-1-positive patients(21/87, 24.14%) was lower than that of patients with negative expression of GLUT-1(24/31, 77.42%) (χ²=27.503, P<0.05) .GATA3, GLUT-1, TNM staging, tumour diameter, and lymph node metastasis were the factors influencing the prognosis of breast cancer(P<0.05). Conclusion: The expressions of GATA3 and GLUT-1 in breast cancer tissues are closely associated with clinicopathological features such as TNM stage and prognosis of patients.

参考文献：

[1] BRAY F, LAVERSANNE M, SUNG H, et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2024, 74(3):229-263.
[2] 顾蓓, 郭斌, 苏群学, 等.乳腺癌组织中Cyclin D1、MYBL2表达及其对预后影响的研究[J].东南大学学报(医学版), 2023, 42(3):411-418.
[3] ZHANG Y, ZHOU Y, MAO F, et al.Ki-67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast cancer recurrence risk:a consecutive cohort study[J].Cancer Commun (Lond), 2020, 40(4):181-193.
[4] 雷少元, 郑荣寿, 张思维, 等.乳腺癌发病率和死亡率的全球模式:一项基于人群的2000—2020年肿瘤登记数据分析研究[J].癌症, 2022, 41(7):324-335.
[5] REISWICH V, SCHMIDT C E, LENNARTZ M, et al.GATA3 expression in human tumors:a tissue microarray study on 16, 557 tumors[J].Pathobiology, 2023, 90(4):219-232.
[6] TAKAKU M, GRIMM S A, DE KUMAR B, et al.Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3[J].Nucleic Acids Res, 2020, 48(9):4756-4768.
[7] 王丹, 张洁, 刘辉勇.EGFR、PRDX4、GLUT-1在口腔鳞癌组织中的表达水平及其临床意义[J].中南医学科学杂志, 2024, 52(3):456-459.
[8] OKCU O, SEN B, OZTURK C, et al.GLUT-1 expression in breast cancer[J].Turk Patoloji Derg, 2022, 38(2):114-121.
[9] LIN J, DING Q, ZHANG G, et al.Study on PI3k gene expression in breast cancer samples and its association with clinical factors and patient survival[J].Cell Mol Biol, 2022, 67(4):321-327.
[10] KATSURA C, OGUNMWONYI I, KANKAM H K, et al.Breast cancer:presentation, investigation and management[J].Br J Hosp Med(Lond), 2022, 83(2):1-7.
[11] JOKAR N, VELIKYAN I, AHMADZADEHFAR H, et al.Theranostic approach in breast cancer:a treasured tailor for future oncology[J].Clin Nucl Med, 2021, 46(8):e410-e420.
[12] 张雪, 董晓平, 管雅喆, 等.女性乳腺癌流行病学趋势及危险因素研究进展[J].肿瘤防治研究, 2021, 48(1):87-92.
[13] 骆广涛, 汤为香, 叶元滋, 等.AR在ER阳性和阴性乳腺癌中的表达及临床意义[J].临床与实验病理学杂志, 2022, 38(5):526-531.
[14] QUERZOLI P, PEDRIALI M, RINALDI R, et al.GATA3 as an adjunct prognostic factor in breast cancer patients with less aggressive disease:a study with a review of the literature[J].Diagnostics(Basel), 2021, 11(4):604.
[15] YOON E C, WANG G, PARKINSON B, et al.TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma[J].Hum Pathol, 2022, 125:97-107.
[16] DIDONNA S C, NAGORNYUK A, ADHIKARI N, et al.P4HTM:a novel downstream target of GATA3 in breast cancer[J].Res Sq, 2023:rs.3.rs-2622989.
[17] 张然, 王健.基于生物学数据库GATA3在乳腺癌中表达和预后及相关分子信号分析[J].中华肿瘤防治杂志, 2021, 28(8):592-597.
[18] 白紫元, 张巧, 杨哲.葡萄糖转运蛋白1在肿瘤细胞代谢重编程中的作用[J].中国生物化学与分子生物学报, 2023, 39(11):1554-1561.
[19] 张媛媛, 陈选英, 薛晓会.GLUT-1、VEGF表达与鼻咽癌发生发展及MVD的关系[J].实用癌症杂志, 2021, 36(5):701-704.
[20] 管洁, 戴北飞, 何丹, 等.乳腺癌中葡萄糖转运蛋白-1和p53蛋白表达水平与临床病理特征及预后的关系[J].临床医药实践, 2022, 31(10):764-767.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录